ReviewNigerian medical journal : journal of the Nigeria Medical Association
Exploring the Relationship Between Angiogenesis Inhibition of sFLT-1 and Sickle Cell Nephropathy.
Review in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sickle cell anaemia (SCA) is a chronic haemoglobinopathy associated with multi-organ complications, among which nephropathy remains a significant cause of morbidity and mortality. Early detection of sickle cell nephropathy (SCN) is crucial, yet conventional markers such as serum creatinine and estimated glomerular filtration rate (eGFR) often fail to detect early renal impairment. Emerging biomarkers like soluble fms-like tyrosine kinase-1 (sFLT-1) have shown potential in identifying early endothelial and glomerular injury in SCA. This study explores the role of angiogenesis inhibition via sFLT-1 in the pathogenesis of renal injury in SCD, aiming to identify correlations between elevated sFLT-1 levels, proteinuria, and declining renal function. Methodology: A cross-sectional analytical study was conducted involving confirmed SCD patients and age- and sex-matched controls. Serum sFLT-1 levels were measured using enzyme-linked immunosorbent assay (ELISA). At the same time, renal function was assessed through estimated glomerular filtration rate (eGFR), serum creatinine, and urinary microalbumin and microalbumin: creatinine ratio quantification. Statistical analyses included correlation studies and group comparisons to determine the association between sFLT-1 concentrations and renal impairment indicators. Results: SCD patients demonstrated significantly elevated sFLT-1 levels compared to controls (p < 0.001). Higher sFLT-1 levels were strongly associated with increased albuminuria and reduced eGFR, indicating early renal damage. These findings suggest that elevated sFLT-1 contributes to glomerular endothelial dysfunction, possibly via inhibition of vascular endothelial growth factor (VEGF)-mediated repair mechanisms. Conclusion: The study reveals a significant relationship between angiogenesis inhibition by sFLT-1 and renal dysfunction in individuals with SCD. sFLT-1 may serve as a promising early biomarker for SCD nephropathy and a potential therapeutic target to preserve renal function in this vulnerable population. Furthermulticentred and longitudinal studies are recommended to establish causality and explore interventional strategies.
Indexed as
Identifiers
42534585PMC13420732What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.